A Phase 1, Double-Blind, Randomized, Placebo-controlled, Single Dose Study of FlecIH-101 (Flecainide Acetate Inhalation Solution) to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs Flecainide (Primary)
- Indications Paroxysmal atrial fibrillation
- Focus Adverse reactions
- Sponsors InCarda Therapeutics
- 10 Jul 2019 Actual date last participant enrolled: 2/1/2019
- 10 Jul 2019 Planned number of patients changed from 15 to 21.
- 10 Jul 2019 Status changed from not yet recruiting to completed.